---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-23-000070"
form_type: "8-K/A"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2023-08-16T23:59:59+00:00"
generated_at: "2026-06-11T08:17:17.135984+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Amphastar files BAQSIMI financials: 2022 revenue $139.3M, revenue less direct expenses $59.8M

## Summary
- BAQSIMI 2022 revenue $139.3M (up 23% YoY from $113.2M); revenue less direct expenses $59.8M vs -$2.3M in 2021.
- Q1 2023 revenue $31.4M, up 7.5% YoY from $29.2M; revenue less direct expenses $13.0M vs $9.2M.
- Acquisition terms: $500M cash at closing, $125M at one-year anniversary, plus up to $450M in sales milestones.
- Net intangible assets of BAQSIMI were $100.3M as of Dec 31, 2022; total assets acquired $187.6M.
- Audited abbreviated financial statements cover FY 2021-2022; unaudited for Q1 2023 and 2022.

## SEC filing metadata
- accession: 0001297184-23-000070
- form_type: 8-K/A
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2023-08-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000070/0001297184-23-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000070/amph-20230630x8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-23-000070
- JSON: https://secwatch.observer/filing/0001297184-23-000070.json
- Plain text: https://secwatch.observer/filing/0001297184-23-000070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.